Asthma is a common disease-state that has a high societal cost, especially in the treatment of severe asthma. This research evaluated whether the initiation of dupilumab, a biologic indicated for asthma, reduced asthma-related emergency department visits or hospitalizations, the number of asthma rescue medications used, and the total cost of asthma-related exacerbations among MassHealth members. The data showed a reduction in emergency department visits and hospitalizations as well as the number of asthma rescue medications used; however, these findings were not statistically significant.
Poster
A Pre-Post Evaluation of Health Care Utilization and Costs Among Patients with Asthma Initiating Dupilumab in a Medicaid Population
Karen Stevens, PharmD
Clinical Consultant Pharmacist, Clinical Pharmacy Services
Thomas Pomfret, PharmD, MPH, BCPS
Clinical Consultant Pharmacist Team Lead and Residency Program Director, Clinical Pharmacy Services
Karen Clements, ScD
Senior Project Director, Research and Evaluation
Pavel Lavitas, PharmD, BCPS
Clinical Team Lead, Clinical Pharmacy Services
Kimberly Lenz, PharmD, MBA, FAMCP
Senior Pharmacy Director, MassHealth/Office of Clinical Affairs
UMASS_Poster_AMCP-22_PrePostEvalHCUCAPAsthmaIDMP_v7_2022.pdf